Avenue Therapeutics, Inc.
corporate_fare Company Profile
Avenue Therapeutics, Inc. (OTC:ATXI) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 5 items for ATXI at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-06, rated 8/10. Across its 5 most recent items scored 7 or higher, the top rating is 9/10, with 4 rated 8 or above. Recent SEC coverage for ATXI spans 10-Q, 8-K, SCHEDULE 13D/A.
Recent high-impact activity:
- Avenue Therapeutics Q3: Cash Down to $1.5M, Going Concern Reaffirmed
- Avenue Therapeutics Reiterates Going Concern Warning as Cash Drops to $1.9M
- Avenue Therapeutics Discloses Going Concern, Limited Cash Runway, and Inability to Access Capital Markets
- Avenue Therapeutics Licenses ATX-04 for Pompe Disease, Bolstering Rare Disease Pipeline
- Fortress Biotech Increases Stake in Avenue Therapeutics to 13.4% via Annual Equity Grant
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 1 shares in ATXI as of the October 30, 2026 settlement, unchanged from the prior period — about 1.0 days to cover at its recent average daily volume. On November 18, 2026, 0.5% of ATXI volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.